Liver Cancer Drugs: Market Research Report

Date: April 22, 2010
Pages: 506
Price:
US$ 3,950.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: L82EA76A20DEN
Leaflet:

Download PDF Leaflet

Liver Cancer Drugs: Market Research Report
This report analyzes the Global market for Liver Cancer Drugs in US$ Million.

Annual estimates and forecasts are provided for the period 2007 through 2015.

The report profiles 40 companies including 4SC AG, Actavis Group, Inc., Alnylam Pharmaceuticals, Inc., ArQule, Inc., Bayer Schering Pharma AG, Bristol-Myers Squibb Company, Celsion Corp, Eli Lilly & Company, ImClone Systems Inc., F. Hoffmann–La Roche Ltd., Jennerex Biotherapeutics, Inc., Onyx Pharmaceuticals, Inc., Pfizer Inc., Progen Pharmaceuticals Ltd., and Teva Pharmaceutical Industries Ltd.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.MARKET OVERVIEW & DYNAMICS

Current Scenario and Outlook
Asians Lead in Liver Cancer Prevalence and Incidence

Table 1. Incidence and Mortality of Liver Cancer in Select Countries: 2007 (includes corresponding Graph/Chart)

Disparity in Epidemiology and Etiology Of Liver Cancer
Liver Cancer Incidence Rising in the US
HCC Incidence Declines in Japan
Conventional Therapies Plagued with Lower Penetration
Therapies and Eligible Patient Population
Major Target Population Exists for Targeted Therapies
Nexavar – The Only Approved Targeted Therapy in Liver Cancer

Table 2. Global Nexavar Sales (2007-2015) (in US$ Million) (includes corresponding Graph/Chart)

Japanese Approval for Nexavar® in 2009
Nexavar Proves Efficacy in Asian Patients
Nexavar Ongoing Clinical Trials
Nexavar Being Evaluated As Adjuvant Therapy
Development of Nexavar Plus Tarceva Therapy Underway
Liver Cancer Treatment to Boost Nexavar’s Revenues
ThermoDox Likely to Enter Market in 2011

Table 3. Worldwide ThermoDox Sales: 2011-2015 (includes corresponding Graph/Chart)

Liver Cancer Therapy – Attracting Increasing Research Efforts
Combination Drugs to Make an Impact
Pipeline Drugs in Liver Cancer Treatment - A Snapshot
Select Pipeline Drugs in Phase III Clinical Trials for Liver Cancer Treatment
Select Pipeline Drugs in Phase II Clinical Trials for Liver Cancer Treatment
Select Pipeline Drugs in Other Clinical Trial Stages for Liver Cancer Treatment
Overview of Select Drugs In Pipeline
Sutent® (Pfizer)
ThermoDox + RFA (Celsion Corp.)
Sorafenib + TACE (Bayer)
Sorafenib + Tegafur/Uracil
Muparfostat (Formerly PI-88) (Progen Pharmaceuticals/ Global TransBiotech)
Avastin + Tarceva (Roche/Genentech)
NX-1207 (Nymox Pharmaceutical Corp.)
ALN-VSP (Alnylam Pharmaceuticals, Inc.)
AV-951 (Aveo Pharmaceuticals)
JX-594 (Jennerex)
Afinitor/RAD001 (Novartis)

4SC-201 (4SC)

CTCE-9908 (Chemokine Therapeutics)
ARQ 197 (ArQule, Inc.)

2.DISEASE OVERVIEW

Liver – A Vital Organ
Functions of the Liver
Overview of Liver Cancer
Benign Liver Tumors
Types of Benign Liver Tumors
Hemangiomas
Hepatic Adenomas
Focal Nodular Hyperplasia
Malignant Liver Tumors
Types of Liver Cancer
Hepatocellular Carcinoma (HCC)
Cholangiocarcinomas
Hepatoblastoma
Hemangiosarcomas and Angiosarcomas
Hepatoblastoma
Secondary Liver Cancer or Metastatic Cancer
Risk Factors
Symptoms of Liver Cancer
Tests for Detection of Liver Cancer
Diagnosis of Liver Cancer
Blood Tests
Imaging Studies
Ultrasound
Computed Tomography
Magnetic Resource Imaging
Angiography

FDG-PET

Biopsy
Prognosis of Liver Cancer
Treatment Of Liver Cancer
Targeted Therapy
Working of Targeted Cancer Therapies
Development of Targeted Therapies
Effect of Targeted Therapies on the Treatment of Cancer
Chemotherapy
Surgery
Side Effects and Risks Associated with Surgery
Cryosurgery
Benefits of Cryosurgery
Limitations of Cryosurgery
Liver Transplant
Side effects and Risks Associated with Liver Transplantation
Tumor Embolization and Ablation
Radiation Therapy
Side-effects Associated with Radiation Therapy
Radiofrequency Ablation
Hepatic Artery Chemoembolization
A Focus on Hepatocellular Carcinoma
Epidemiology
Pathogenesis
Pathology
Prognosis and Staging
Treatment
Treatment Follow-up

3.NEXAVAR’S APPROVALS IN REGIONAL MARKETS

Bayer Secures Japanese Approval for Nexavar®
Bayer Obtains Approval for Nexavar in China
Bayer Obtains Approval for Marketing Nexavar® in Singapore
Bayer Receives Health Canada's Approval for Nexavar
Bayer Obtains FDA Approval for Nexavar in Treating Liver Cancer
Bayer Receives EU Clearance for Marketing Nexavar

4.RECENT INDUSTRY ACTIVITY

NICE Refuses to Take Nexavar on National Health Service (NHS)
Delcath’s Doxorubicin Obtains Orphan-Drug Designation from FDA
CACMS Obtains Clearance for Traditional Chinese Medicine for Liver Cancer
Curetech Obtains FDA Approval to Commence Trial on CT-011
Bayer Mulls Over Legal Recourse to Avert Nexavar’ Generic in India
Jennerex Generates Funds for Developing JX-594
Celsion to Extend ThermoDox Phase III Trial to Japan
Bayer Commences Phase III trials on Nexavar and Tarceva Combination Therapy
Tiandiren Pharma Begins Construction of Biotech Park
Can-Fite to Commence Phase I/II Trial of CF102
Celsion’s ThermoDox Obtains Orphan Drug Designation from FDA
Alnylam Obtains FDA Clearance to Commence Phase I Trial on ALN-VSP
ArQule Enrolls Patients for Phase II Study with ARQ 197 in Hepatocellular Carcinoma
PharmaSynth Licenses Muparfostat to Global TransBiotech
Bayer-Onyx Commences Clinical Trials on Nexavar as Adjuvant Therapy
Protherics Begins Phase II Clinical Trial on Prolarix
Chemokine Obtains Hong Kong DoH Clearance on CTCE-9908
AstraZeneca Forges New Alliance for Anti-Cancer Compounds
BioAlliance Annuls Trials on Transdrug® for Liver Cancer Treatment
Chemokine Obtains Health Canada Approval to Start CTCE-9908 Phase II Trial
Progen Pharmaceuticals Spins-Off its Manufacturing Business
Metabasis Obtains EMEA Orphan Drug Designation for Liver Cancer Drug
Metabasis Obtains FDA Orphan Drug Designation for Liver Cancer Drug

5.FOCUS ON SELECT GLOBAL PLAYERS

4SC AG (GERMANY)

Actavis Group, Inc. (USA)
Alnylam Pharmaceuticals, Inc. (USA)
ArQule, Inc. (USA)
Bayer Schering Pharma AG (Germany)
Bristol-Myers Squibb Company (US)
Celsion Corp. (USA)
Eli Lilly & Company (US)
ImClone Systems Inc.
F. Hoffmann–La Roche Ltd. (Switzerland)
Jennerex Biotherapeutics, Inc. (USA)
Onyx Pharmaceuticals, Inc. (USA)
Pfizer Inc. (USA)
Progen Pharmaceuticals Ltd. (Australia)
Teva Pharmaceutical Industries Ltd. (Israel)

6.GLOBAL MARKET PERSPECTIVE

Table 4. World Recent Past, Current & Future Analysis for Liver Cancer Drugs Market Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 50 (including Divisions/Subsidiaries - 54)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle East
Skip to top


Cancer Liver Cancer Therapy Area Pipeline Report US$ 1,495.00 Jan, 2010 · 401 pages
Liver Cancer Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 419 pages
Pancreatic Cancer Drugs: Market Research Report US$ 3,450.00 Apr, 2010 · 405 pages
Kidney Cancer Drugs: Market Research Report US$ 4,500.00 May, 2012 · 297 pages

Ask Your Question

Liver Cancer Drugs: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: